Sunitinib and other targeted therapies for renal cell carcinoma
2011
Targeted Therapy for Renal Cancer
publication
Evidence: high
Author Information
Author(s): Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T
Primary Institution: St Bartholomew's Hospital London, Barts and the London NHS trust
Conclusion
Targeted therapy has significantly improved the treatment and overall survival of patients with metastatic renal cancer.
Supporting Evidence
- Sunitinib has established itself as the standard first-line therapy for clear cell renal carcinoma.
- The progression-free survival for sunitinib is significantly better than for interferon.
- Newer agents are under investigation to improve treatment outcomes.
Takeaway
Doctors now have special medicines that help treat kidney cancer better than before, making patients live longer.
Methodology
This review discusses the current understanding of targeted therapies in renal cancer and highlights areas needing further research.
Limitations
The review does not provide new clinical trial data but summarizes existing knowledge and ongoing research.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.45–0.64
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website